Accelerating the Progress of Scleroderma Research
CONQUEST is a global, perpetual, clinical trial platform developed by the Scleroderma Research Foundation (SRF) in coordination with partner biopharmaceutical companies to accelerate the clinical development of agents for scleroderma.
This groundbreaking effort, led by the SRF, will enroll patients across more than 130 centers in more than 22 countries. CONQUEST offers advantages to all stakeholders— patients, physician, and drug innovators— and provides for a seamless transition to a global Phase 3 trial, investigation of a drug’s activity in a wide range of genetic backgrounds, as well as rapid patient enrollment. In the initial stages, the primary objective of CONQUEST is to accelerate the evaluation of the treatments for SSc-ILD (interstitial lung disease secondary to scleroderma).
By assembling a global network of high-performing centers that are dedicated to treating scleroderma, the SRF expects to make enduring contributions to the scleroderma community by creating an ecosystem designed to enable success in new drug development.
CONQUEST is anticipated to start enrolling patients in the near future. We would encourage individuals who have SSc-ILD to consider participation in CONQUEST. Additional information about the trial and how to participate will be available in the coming months.
About CONQUEST
At this stage, the primary objective of CONQUEST is to rapidly evaluate potential treatments for interstitial lung disease associated with systemic sclerosis (SSc-ILD). Secondary objectives include global SSc outcomes, including some focused on skin and other aspects of the disease.
Learn more about CONQUEST.
This platform clinical trial is the first of its kind in rare autoimmune diseases.
The CONQUEST Steering Committee
Meet the people providing external oversight of CONQUEST.
We are on a mission.
At the Scleroderma Research Foundation, we can’t and won’t stop until we find a cure for scleroderma. Learn more about our world-class research program and educational offerings.
